Skip to main content


Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

Fig. 1

Adjusted transplantation outcomes of patients receiving R-RIC (interrupted lines) and nonR-RIC (solid line) regimens. a Cumulative incidence of chronic graft-versus-host-disease. b Cumulative incidence of non-relapse mortality. c Cumulative incidence of lymphoma relapse/progression. d Progression-free survival. e Overall survival

Back to article page